Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1007
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2007  |  Volume : 55  |  Issue : 2  |  Page : 127-131

A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan® in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension


1 Medical Research Foundation, Sankara Nethralaya, Chennai, India
2 Medical Research Division, Pfizer Ltd., Mumbai, India

Correspondence Address:
Arun Narayanaswamy
Glaucoma Services, Sankara Nethralaya, Medical Research Foundation, 18, College Road, Chennai - 600 006
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.30707

Rights and Permissions

Aim: To compare the efficacy and tolerability of Xalatan® with generic latanoprost (Latoprost) in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OH). Materials and Methods: This was a single-center, randomized, open label, crossover, two period comparative study. At the baseline visit, subjects were randomized to two groups. Group A received Xalatan® for weeks 1-12 followed by Latoprost for weeks 13-24. Group B received Latoprost for weeks 1-12 followed by Xalatan® for weeks 13-24. Results: 30 subjects were recruited, 12 in Group A and 18 in Group B. In subjects administered Xalatan®, intraocular pressure (IOP) showed a greater decrease ( P <0.001) from 23.64 ± 3.13 mmHg at baseline to 14.29 ± 1.61 mmHg at week 12 (fall of 9.35 ± 3.55 mmHg, 38.66% ± 10.29) than that seen in the Latoprost group (22.74 ± 2.47 mmHg to 16.98 ± 2.49 mmHg, fall of 5.76 ± 1.41 mmHg; 25.42% ± 5.98). In period 2 when subjects were crossed over to Xalatan® from Latoprost, there was a further fall from 16.98 ± 2.49 mmHg to 16.09 ± 1.49 at week 24 (fall of 0.89 ± 1.59 mmHg; 4.3% ± 8.76). However, when subjects were crossed over to Latoprost from Xalatan®, the IOP rose from 14.29 ± 1.61 mmHg to 15.36 ± 1.71 mmHg at week 24 (8.86% ± 17.76). There was no significant difference in incidence of conjunctival hyperemia or any other adverse events in both the groups. Conclusion: The magnitude of IOP lowering in patients with POAG and OH with Xalatan® and Latoprost is different. In our study, the IOP lowering with Xalatan® was higher than that with Latoprost.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed9563    
    Printed516    
    Emailed26    
    PDF Downloaded1086    
    Comments [Add]    
    Cited by others 9    

Recommend this journal